BioXcel Therapeutics (BTAI) Amortization of Deferred Charges (2022 - 2026)

BioXcel Therapeutics' Amortization of Deferred Charges history runs 5 years deep, the most recent figure standing at $502000.0 for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges rose 43.43% year-over-year to $502000.0; the TTM figure through Mar 2026 stood at $5.6 million (down 18.44% YoY), while the FY2025 annual figure was $5.4 million, down 16.95% from the prior year.
• Amortization of Deferred Charges was $502000.0 for Q1 2026 at BioXcel Therapeutics, down from $4.3 million in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $6.3 million in Q4 2024 to a low of $43000.0 in Q1 2024.
• Historically, Amortization of Deferred Charges has averaged $919562.5 across 5 years, with a median of $341500.0 in 2023.
• Biggest YoY gain for Amortization of Deferred Charges was 1951.47% in 2024; the steepest drop was 87.09% in 2024.
• A 5-year view of Amortization of Deferred Charges shows it stood at $322000.0 in 2022, then fell by 4.66% to $307000.0 in 2023, then jumped by 1951.47% to $6.3 million in 2024, then sank by 32.5% to $4.3 million in 2025, then plunged by 88.19% to $502000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $502000.0 (Q1 2026), $4.3 million (Q4 2025), and $441000.0 (Q3 2025), per Business Quant data.